Using gnomAD non‐cancer subjects as a control group, potential germline pathogenic CHEK2 variants were associated with a 2.8‐fold increased risk (95% CI 1.8–4.6, p < 0.01) of AGCT. Here, CHEK2 is linked to cancer.